Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

Exclusion Criteria

• •Bilateral or metastatic breast cancer
• •Receiving neoadjuvant treatment
• •Other malignancies within 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer
• •Severe systemic infections or other serious illnesses
• •HIV infection, active hepatitis B or C infection
• •Known allergy to or intolerance to a therapeutic drug or its excipients
• •Prior history of chemotherapy, endocrine therapy, biotherapy, or radiation therapy for any reason
• •Enrollment of another investigational study within 4 weeks prior to initial administration of the investigational treatment
• •Receiving live vaccine within 30 days prior to initial administration of the investigational treatment
• •History of mental illness or drug abuse that may affect compliance with the trial requirements
• •The researchers determine that the patients were not suitable for the study